SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (465)6/24/2004 12:43:33 PM
From: quidditch  Read Replies (1) of 933
 
Thanks, Peter. A couple of follow-up questions:

How does this affect the potential addressable market? Is oxaliplatin the gold standard for colorectal cancer? Is it the primary, or only, chemo regimen prescribed as a first line treatment of those types of colorectal for which EPO-862 was trialed?

Is the method of action of oxaliplatin similar to other meds such that epo would be encountering possible DLTs there as well.

I know these call for speculation, but I'm trying to understand the parameters of the cumulative effect of EPO-862 and oxaliplatin.

Another question: is sensory neuropathy a condition where the patient experiences a lack of sensory inputs or experiences pain or other sensations where there might be no specific physical cause for the sensations, other then the effect of the drug? Sorry for the d... a.. question: I've seen references to sensory neuropathy a lot and don't know what it is.

Thanks,

quid
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News